Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial
Niekbachsh Mohammadnia, Britta E. Wesselink, Willem A. Bax, Stefan Mark Nidorf et autres
Background The LoDoCo2 (Low‐Dose Colchicine 2) trial showed that colchicine reduced the risk for cardiovascular events in patients with chronic coronary syndrome. Current guidelines recommend colchicine use in selected high‐risk patients. The aim of this secondary analysis was to explore the relative …
nl, us, au, ca (code pays fourni par la source)
13 citations
Journal of the American Heart Association